首页> 美国卫生研究院文献>other >Prognostic Outcomes and Risk Factors for Patients with Renal Cell Carcinoma and Venous Tumor Thrombus after Radical Nephrectomy and Thrombectomy: The Prognostic Significance of Venous Tumor Thrombus Level
【2h】

Prognostic Outcomes and Risk Factors for Patients with Renal Cell Carcinoma and Venous Tumor Thrombus after Radical Nephrectomy and Thrombectomy: The Prognostic Significance of Venous Tumor Thrombus Level

机译:根治性肾切除和血栓切除术后肾细胞癌和静脉肿瘤血栓患者的预后结果和危险因素:静脉肿瘤血栓水平的预后意义

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Introduction. To evaluate the prognostic outcomes and risk factors for renal cell carcinoma (RCC) patients with venous tumor thrombus in China. Materials and Methods. We reviewed the clinical information of 169 patients who underwent radical nephrectomy and thrombectomy. Overall and cancer-specific survival rates were analyzed. Univariate and multivariate analyses were used to investigate the potential prognostic factors. Results. The median survival time was 63 months. The five-year overall survival and cancer-specific survival rate were 53.6% and 54.4% for all patients. For all patients, significant survival difference was only observed between early (below hepatic vein) and advanced (above hepatic vein) tumor thrombus. However, significant differences existed between both RV/IVC and early/advanced tumor thrombus groups in N0M0 patients. Multivariate analysis demonstrated that higher tumor thrombus level (p = 0.016, RR = 1.58), N (p = 0.013, RR = 2.60), and M (p < 0.001, RR = 4.14) stages and adrenal gland invasion (p = 0.001, RR = 4.91) were the most significant negative prognostic predictors. Conclusions. In this study, we reported most cases of RCC patients with venous extension in China. We proved that patients with RCC and venous tumor thrombus may have relative promising long-term survival rate, especially those with early tumor thrombus.
机译:介绍。在中国评估肾细胞癌(RCC)静脉肿瘤血栓患者的预后结果和危险因素。材料和方法。我们回顾了169例行根治性肾切除和血栓切除术的患者的临床信息。分析了总体生存率和癌症特异性生存率。单因素和多因素分析用于研究潜在的预后因素。结果。中位生存时间为63个月。所有患者的五年总生存率和癌症特异性生存率分别为53.6%和54.4%。对于所有患者,仅在早期(肝静脉下方)和晚期(肝静脉上方)肿瘤血栓之间观察到明显的生存差异。但是,N0M0患者的RV / IVC与早期/晚期肿瘤血栓组之间存在显着差异。多变量分析表明,较高的肿瘤血栓水平(p = 0.016,RR = 1.58),N(p = 0.013,RR = 2.60)和M(p <0.001,RR = 4.14)分期和肾上腺浸润(p = 0.001, RR = 4.91)是最显着的阴性预后指标。结论。在这项研究中,我们报道了中国大多数RCC患者静脉扩张的病例。我们证明,RCC和静脉肿瘤血栓的患者可能具有相对有希望的长期生存率,尤其是那些早期肿瘤血栓的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号